Sobi begins patient enrolment in A-SURE study haemophilia A treatment

Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news